<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634475</url>
  </required_header>
  <id_info>
    <org_study_id>PP-001-1001</org_study_id>
    <nct_id>NCT03634475</nct_id>
  </id_info>
  <brief_title>A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis</brief_title>
  <official_title>A Safety Study of Intravitreal PP-001 in Patients With Chronic, Non-Infectious Uveitis Having Chronic Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panoptes Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Panoptes Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, PP-001 is assessed for safety and efficacy in patients diagnosed with
      non-infectious chronic uveitis. PP-001 is a novel small molecule that inhibits a specific
      enzyme (Dihydroorotate Dehydrogenase) and has shown pre-clinical efficacy in treatment of
      non-infectious uveitis. PP-001 will be administered to participants as a single intravitreal
      injection in ascending doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study assesses safety and efficacy of PP-001 after intravitreal injection in patients
      diagnosed with non-infectious chronic uveitis. PP-001 is a novel small molecule inhibitor of
      Dihydroorotate Dehydrogenase (DHODH) and has shown pre-clinical efficacy in treatment of
      non-infectious uveitis. PP-001 is to offer a local treatment alternative to corticosteroids
      with the objective to reduce or possibly replace steroid intake of non-infectious uveitis
      patients. In the current study, PP-001 will be injected in ascending doses into the vitreous
      body of the eye of study participants who suffer from non-infectious uveitis. Participants
      will be monitored for safety and efficacy evaluation of the study drug.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability by determining treatment emergent adverse events</measure>
    <time_frame>40 days</time_frame>
    <description>To assess safety and tolerability of ascending doses of PP-001 in participants with chronic, non-infectious uveitis when administered as single intravitreal injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of improvement of ocular inflammation between baseline and follow-up visits using slit-lamp examinations</measure>
    <time_frame>40 days</time_frame>
    <description>To assess the improvement of inflammation using slit lamp examinations in participants with chronic, non-infectious uveitis after ascending doses of PP-001 when administered as single intravitreal injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of improvement of ocular inflammation between baseline and follow-up visits using Optical Coherence Tomography (OCT) examinations</measure>
    <time_frame>40 days</time_frame>
    <description>To assess the improvement of inflammation using OCT examinations in participants with chronic, non-infectious uveitis after ascending doses of PP-001 when administered as single intravitreal injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Peak Plasma Concentration (Cmax) in peripheral blood</measure>
    <time_frame>2 days</time_frame>
    <description>To evaluate the pharmacokinetics (Cmax) in participants with chronic, non-infectious uveitis after ascending doses of PP-001 when administered as single intravitreal injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Area under the plasma concentration versus time curve (AUC) in peripheral blood</measure>
    <time_frame>2 days</time_frame>
    <description>To evaluate the pharmacokinetics (AUC) in participants with chronic, non-infectious uveitis after ascending doses of PP-001 when administered as single intravitreal injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Non-infectious Uveitis</condition>
  <arm_group>
    <arm_group_label>PP-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection of 3 up to 4 doses of PP-001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP-001</intervention_name>
    <description>Drug - no placebo</description>
    <arm_group_label>PP-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients at the age of 18 years or older who have diagnosis of chronic,
             posterior uveitis, intermediate uveitis or panuveitis

        Exclusion Criteria:

          -  Patients receiving specific medication/interventions as specified per protocol

          -  Pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panoptes Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Panoptes Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charit√© Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotterdam Eye Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Eye Hospital</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorefields Eye Hospital</name>
      <address>
        <city>Moorfields</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

